► 2:08 Mitochondrial Metabolism Inhibitors as a CML Treatment? CML Content Hub @VignirHelgason, of @UofGlasgow, discusses #mitochondrial #metabolic #inhibitors for #CML.
► 1:41 Risk Stratifying CML Patients for Cardiovascular Adverse Events When Choosing First-Line Therapy CML Content Hub @mjmauroMD, of @MSKCancerCenter, discusses #risk stratification and #TKI selection in #CML.
► 1:53 5-Year Results Solidify Bosutinib’s Increased Efficacy vs Imatinib CML Content Hub @GCC_Cortes of @GACancerCenter discusses #bosutinib in #CML.
► 2:28 Optimizing CML Treatment: Latest Clinical Trial Data on TKI Efficacy and Dosage CML Content Hub @CoplandMhairi, of @UofGlasgow, discusses #TKI efficacy and #dosage.
► 1:31:53 CML Management and Emerging Therapies CML Content Hub Ehab Atallah, MD, of @MedicalCollege, and @mjmauroMD, of @MSKCancerCenter, discuss #emerging #therapies for #CML.
► 01:25 Nilotinib Therapy in Frontline CML CML Content Hub Timothy Hughes, of SAHMRI, discusses #frontline #nilotinib therapy in #CML.
► 5:06 Prior Bariatric Surgery: Suggestive of Worse Outcomes in CML Patients CML Content Hub @FadiHaddad_MD of @MDAndersonNews, discusses #bariatric surgery in #CML.
► 2:19 Promising Two-Year Trial Data on Asciminib vs Bosutinib CML Content Hub Timothy Hughes, MD, of @sahmriAU, discusses improved #outcomes with #asciminib.
► 1:01 Progress Toward Treatment Discontinuation in CML CML Content Hub @GCC_Cortes of @GACancerCenter discusses treatment #discontinuation among patients with #CML.
► 46:54 Multidisciplinary Management of Chronic Myeloid Leukemia in the Later-Line Setting CML Content Hub Experts discuss the importance of a #multidisciplinary #team in the #management of #CML.
